Skip to main content

Biohaven Ltd 8-K, filed Oct 29, 2026

Biohaven Ltd. (BHVN)

8-K 2026-10-29 For: 2026-10-29
View Original
Added on October 29, 2026

About this 8-K

Biohaven Ltd filed this 8-K on October 29, 2026.

Biohaven's new drug application resubmission for Vyglxia (troriluzole) in spinocerebellar ataxia was accepted for review by the FDA, with a user fee goal date in the first quarter of 2027. The company reported a net loss of $129.3 million, or $0.86 per share, for the three months ended September 30, 2026. Cash, cash equivalents, marketable securities and restricted cash totaled approximately $164.0 million as of September 30, 2026. AI summary

Items reported

  • Item 2.02: Financial results
  • Item 9.01: Financial statements and exhibits